First robotic lung transplant in Abu Dhabi, UAE, Gulf Today, July 8, 2025

Cleveland Clinic Abu Dhabi has achieved a historic milestone by performing the Gulf region’s first robotic lung transplants, making it one of only five centers worldwide to successfully complete this advanced procedure. Two patients with idiopathic pulmonary fibrosis and secondary pulmonary hypertension have undergone the surgery. These surgeries were quite complex due to pulmonary hypertension, […]

First robotic lung transplant in Abu Dhabi, UAE, Gulf Today, July 8, 2025 Read Post »

The Pulmonary Hypertension Global Patient Survey: understanding the experiences and perspectives of patients, European Respiratory Journal Open Research 2025

The key findings from the Pulmonary Hypertension Global Patient Survey (PHGPS) adult cohort of 3,329 patients have been published in the ERJ Open Research 2025, highlighting the achievements, shortcomings & regional disparities of clinical care & research globally. The Pulmonary Hypertension Global Patient Survey represents the most extensive survey of its type in the pulmonary

The Pulmonary Hypertension Global Patient Survey: understanding the experiences and perspectives of patients, European Respiratory Journal Open Research 2025 Read Post »

Phase 3 pulmonary arterial hypertension trial of ralinepag now fully enrolled, results are expected in 2026, Pulmonary Hypertension News, June 27, 2025

Ralinepag is a novel prostacyclin receptor agonist. It is designed to mimic prostacyclin, a molecule that reduces blood pressure by relaxing blood vessels. It is a once-daily oral formulation. United Therapeutics has announced the completion of enrollment for its ADVANCE OUTCOMES, a Phase 3 clinical trial testing ralinepag for pulmonary arterial hypertension (PAH). The study

Phase 3 pulmonary arterial hypertension trial of ralinepag now fully enrolled, results are expected in 2026, Pulmonary Hypertension News, June 27, 2025 Read Post »

New study investigates reliability of point of care and remote monitoring for pulmonary arterial hypertension biomarkers NT-proBNP/BNP , Respirology, July 3, 2025

Brain natriuretic peptide (BNP) and N-terminal prohormone of BNP (NT-proBNP) serve as crucial biomarkers in pulmonary arterial hypertension (PAH). Nevertheless, test results are seldom accessible during clinical evaluations. A study published on Respirology on July 3, 2025, examined the reliability of NT-proBNP/BNP point-of-care tests (POCT) in pulmonary arterial hypertension patients and assessed the stability of

New study investigates reliability of point of care and remote monitoring for pulmonary arterial hypertension biomarkers NT-proBNP/BNP , Respirology, July 3, 2025 Read Post »

The landscape of referrals for lung transplantation in pulmonary arterial hypertension: a report from the Pulmonary Hypertension Association Registry, Journal of Heart and Lung Transplantation, June 26, 2025

A large US registry study of 1,671 patients with pulmonary arterial hypertension (PAH) over 4607 person-years of follow up found that lung transplant referrals are occurring far too infrequently and too late in the disease course. Despite professional society recommendations for early referral, only 12% of patients were referred for transplantation over the study period.

The landscape of referrals for lung transplantation in pulmonary arterial hypertension: a report from the Pulmonary Hypertension Association Registry, Journal of Heart and Lung Transplantation, June 26, 2025 Read Post »

Seven Actions Towards Advancing Patient Authorship and Collaboration in Peer-Reviewed Publications, The Patient, July 2, 2025

Jan Geissler, Founder and CEO of Patvocates, is co-author of an article titled “Seven Actions Towards Advancing Patient Authorship and Collaboration in Peer-Reviewed Publications” published on July.2, 2025 on The Patient. In a post for LinkedIn Jan says that patients and patient advocates are often missing from the author lists of scientific publications, even if

Seven Actions Towards Advancing Patient Authorship and Collaboration in Peer-Reviewed Publications, The Patient, July 2, 2025 Read Post »

Menopause and pulmonary hypertension, a new publication by the UK Pulmonary Hypertension Association, PHA UK

Menopause affects many women in the pulmonary hypertension community. This new publication by the UK Pulmonary Hypertension Association, PHA UK, answers common questions, shares real experiences, and brings expert advice to help make things a little easier for patients. Order this free resource on the PHA UK website at this link

Menopause and pulmonary hypertension, a new publication by the UK Pulmonary Hypertension Association, PHA UK Read Post »

Scientists create first mini-lungs with built-in blood vessels, unlocking new insights for pulmonary vascular disease, UCLA Newsroom, July 2, 2025

Researchers at the University of California, Los Angeles (UCLA), have achieved a breakthrough by successfully growing miniature lungs from stem cells that include functioning blood vessel networks for the first time. Published in Cell, this advancement represents a significant step forward because previous lung organoids lacked the essential vascular systems needed for proper lung function.

Scientists create first mini-lungs with built-in blood vessels, unlocking new insights for pulmonary vascular disease, UCLA Newsroom, July 2, 2025 Read Post »

Computer modeling used in study to simulate long-term mortality/morbidity in patients with pulmonary arterial hypertension If sotatercept Is delayed, Advances in Therapy, June 17, 2025

Researchers used computer modeling to compare immediate versus delayed (2-year) treatment with sotatercept, a new pulmonary arterial hypertension medication, to predict lifetime outcomes. Study Method: Building on the findings of the phase 3 STELLAR trial on sotatercept the authors of the study refer to a population health model which was recently published assessing the long-term

Computer modeling used in study to simulate long-term mortality/morbidity in patients with pulmonary arterial hypertension If sotatercept Is delayed, Advances in Therapy, June 17, 2025 Read Post »

Women with pulmonary arterial hypertension rely heavily on caregivers but face major gaps in meeting their support needs, The American Journal of Managed Care, June 18, 2025

A new study presented at the American Thoracic Society 2025 Conference reveals that women with pulmonary arterial hypertension (PAH) rely heavily on family caregivers but face significant gaps in meeting their support needs. Methodology Researchers conducted a 45-minute web-based quantitative survey across multiple countries, targeting women aged 21-50 with pulmonary arterial hypertension. Patient-reported outcome measures

Women with pulmonary arterial hypertension rely heavily on caregivers but face major gaps in meeting their support needs, The American Journal of Managed Care, June 18, 2025 Read Post »

Pulmonary arterial hypertension (PAH): sex-specific differences and outcomes, Therapeutic Advances in Respiratory Disease, Jan-Dec 2025

Pulmonary arterial hypertension has a higher prevalence in women than men, yet notable sex-based differences influence disease presentation, treatment response, and outcomes. Based on data from major pulmonary arterial hypertension clinical trials the authors of a recent study published in Therapeutic Advances in Respiratory Disease have found that: These sex-based differences, say the authors, highlight

Pulmonary arterial hypertension (PAH): sex-specific differences and outcomes, Therapeutic Advances in Respiratory Disease, Jan-Dec 2025 Read Post »

Anti-remodeling therapies in pulmonary arterial hypertension (PAH), Trends in Pharmaceutical Science, June 19, 2025

Existing treatments pulmonary arterial hypertension (PAH) widen blood vessels, can help relieve symptoms and extend life, but cannot cure the disease or repair the damaged vessels. The field is now moving toward treatments that could actually modify the underlying disease process, based on promising laboratory research that’s being tested in patients. Two important breakthroughs include

Anti-remodeling therapies in pulmonary arterial hypertension (PAH), Trends in Pharmaceutical Science, June 19, 2025 Read Post »

Artificial intelligence applied to chest X-rays may have the potential to detect pulmonary hypertension associated with congenital heart disease (PAH-CHD), CHEST Journal, June 18, 2025

Pulmonary hypertension (PH) is hard to diagnose, especially in places with limited medical resources, but catching it early is crucial for treatment. A group of researchers from China conducted a retrospective cohort study with 4,576 patients, including 2,288 pulmonary hypertension cases, who underwent chest X-rays (CXR) followed by right heart catheterization (RHC) or transthoracic echocardiography

Artificial intelligence applied to chest X-rays may have the potential to detect pulmonary hypertension associated with congenital heart disease (PAH-CHD), CHEST Journal, June 18, 2025 Read Post »

PVRI Drug Discovery Symposium, June 16-17: Key Insights, Louise Bouman, Chair of PHA Netherlands and Board Member of the Alliance for Pulmonary Hypertension

Louise Bouman, Chair of Stichting Pulmonale Hypertensie (PHA Netherlands) and Board Member of the Alliance for Pulmonary Hypertension is just back from Amsterdam where she attended the Pulmonary Vascular Institute (PVRI) Symposium on Drug Discovery and Development taking place on June 16-17. “I recently had the opportunity to attend an inspiring symposium organized by the

PVRI Drug Discovery Symposium, June 16-17: Key Insights, Louise Bouman, Chair of PHA Netherlands and Board Member of the Alliance for Pulmonary Hypertension Read Post »

The Role of Psychological Distress on Health-Related Quality of Life, Fatigue, and Pain in Adults With Pulmonary Hypertension, Pulmonary Circulation, June 17, 2025

A study published in Pulmonary Circulation on June 17, 2025 has examined the relationships between fatigue, pain, anxiety, depression, and quality of life in 68 adults with pulmonary hypertension, recruited from global pulmonary hypertensions associations, who completed a series of self-report measures. The researchers found alarmingly high rates of these symptoms: 86.8% experienced clinical levels

The Role of Psychological Distress on Health-Related Quality of Life, Fatigue, and Pain in Adults With Pulmonary Hypertension, Pulmonary Circulation, June 17, 2025 Read Post »

Enrollment completed in ongoing PROSERA Phase 3 study for seralutinib in pulmonary arterial hypertension

Gossamer Bio, Inc. today announced enrollment completion for the ongoing, global registrational Phase 3 PROSERA Study evaluating seralutinib in Functional Class II and III pulmonary arterial hypertension patients. Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a global collaboration agreement. See also our previous article about the PROSERA study at this link

Enrollment completed in ongoing PROSERA Phase 3 study for seralutinib in pulmonary arterial hypertension Read Post »

The ability to reverse damage to your lungs and heart is getting closer: it’s about tricking stem cells into repairing organs, National Geographic, May 16, 2025

When serious illness harms vital organs such as the heart or lungs, physicians typically can only prevent further deterioration. However, following thirty years of research and experimentation, the possibility of activating the body’s natural stem cells to function as sophisticated cellular repair mechanisms is becoming increasingly realistic. Stem cells serve as essential biological production centers

The ability to reverse damage to your lungs and heart is getting closer: it’s about tricking stem cells into repairing organs, National Geographic, May 16, 2025 Read Post »

TRANSLATE »
Scroll to Top